Join
Live feed
·
PRReleasevia Quantisnow
Regulus Therapeutics Inc. logo

Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominant Polycystic Kidney Disease

ByQuantisnow·Wall Street's wire, on your screen.
RGLS· Regulus Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RGLS (Regulus Therapeutics Inc.) and more on Quantisnow.